Benzinga · Aug 12, 2026
Piper Sandler Maintains Neutral on LENZ Therapeutics, Lowers Price Target to $7
Piper Sandler analyst Biren Amin maintains LENZ Therapeutics (NASDAQ:LENZ) with a Neutral and lowers the price target from $12 to $7.
LE
NASDAQ · LENZ
LENZ Therapeutics, Inc.
Healthcare · Biotechnology
$5.96
Up+$0.13 (+2.23%)
Updated Sep 7, 2026, 12:51 AM
SID Score
4.1/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 684.09M
- P/E ratio
- -13.13
- Dividend yield
- 0.00%
- 52-week range
- $4.54 – $50.40
- Volume
- 488.96K
- Avg. volume
- 997.98K
Price performance
LENZ price history
1M range · 20 trading sessions · Daily adjusted prices
LENZ closed at $5.96 after 20 trading sessions, up 11.19% for the selected period.
- Last close
- $5.96
- Period change
- +11.19%
- Period low
- $4.59
- Period high
- $5.96
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 4, 2026 | $5.75 | $5.98 | $5.615 | $5.96 | 488.96K |
| Sep 3, 2026 | $5.90 | $5.97 | $5.65 | $5.83 | 835.14K |
| Sep 2, 2026 | $5.21 | $5.81 | $5.21 | $5.80 | 993.29K |
| Sep 1, 2026 | $5.17 | $5.305 | $5.00 | $5.23 | 605.58K |
| Aug 31, 2026 | $5.06 | $5.275 | $5.008 | $5.21 | 713.74K |
| Aug 28, 2026 | $4.80 | $5.13 | $4.69 | $5.11 | 680.21K |
| Aug 27, 2026 | $4.78 | $4.8328 | $4.7182 | $4.81 | 439.22K |
| Aug 26, 2026 | $4.67 | $4.84 | $4.58 | $4.78 | 546.04K |
| Aug 25, 2026 | $4.58 | $4.81 | $4.58 | $4.67 | 542.23K |
| Aug 24, 2026 | $4.65 | $4.70 | $4.5467 | $4.59 | 497.91K |
| Aug 21, 2026 | $4.71 | $4.81 | $4.67 | $4.68 | 475.32K |
| Aug 20, 2026 | $4.88 | $4.90 | $4.575 | $4.66 | 567.53K |
| Aug 19, 2026 | $4.82 | $5.036 | $4.81 | $4.92 | 583.51K |
| Aug 18, 2026 | $4.77 | $4.89 | $4.74 | $4.77 | 534.41K |
| Aug 17, 2026 | $4.71 | $4.82 | $4.60 | $4.79 | 804.84K |
| Aug 14, 2026 | $4.63 | $4.87 | $4.63 | $4.73 | 702.71K |
| Aug 13, 2026 | $5.02 | $5.25 | $4.535 | $4.60 | 1.43M |
| Aug 12, 2026 | $5.93 | $6.74 | $5.01 | $5.04 | 2.14M |
| Aug 11, 2026 | $5.41 | $5.48 | $5.05 | $5.21 | 530.04K |
| Aug 10, 2026 | $5.38 | $5.4778 | $5.29 | $5.36 | 441.85K |
Latest LENZ news
The latest Smart Investors Daily articles mentioning LENZ.
Stock researchCompany · Overview
LENZ research
Overview
Company profile and research snapshot.
Company profile
LENZ Therapeutics Inc is a late-stage biopharmaceutical company focused on developing and commercializing therapies to improve vision and developing ophthalmic pharmaceutical products.. Its initial focus is the treatment of presbyopia, the inevitable loss of near vision that impacts the daily lives of nearly all people over 45.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- $61.50
- Implied upside
- —
- Analysts
- —
| Date | Firm | Rating | Target |
|---|---|---|---|
| Aug 12, 2026 | Piper Sandler | Neutral | — |
| Jul 7, 2026 | HC Wainwright & Co. | Buy | — |
| May 13, 2026 | Citigroup | Buy | — |
| May 12, 2026 | HC Wainwright & Co. | Buy | — |
| May 12, 2026 | Piper Sandler | Neutral | — |
News briefing
No generated briefing is available yet.
SeekingAlpha · Aug 12, 2026
LENZ Therapeutics, Inc. (LENZ) Q2 2026 Earnings Call Transcript
LENZ Therapeutics, Inc. (LENZ) Q2 2026 Earnings Call August 11, 2026 4:30 PM EDTCompany ParticipantsDaniel Chevallard - Chief Financial OfficerEvert...
Benzinga · Aug 11, 2026
LENZ Therapeutics Q2 EPS $(1.02) Beats $(1.06) Estimate, Sales $5.486M Beat $2.373M Estimate
LENZ Therapeutics (NASDAQ:LENZ) reported quarterly losses of $(1.02) per share which beat the analyst consensus estimate of $(1.06) by 3.77 percent. This is a 92.45 percent decrease over losses of $(0.53) per share from
Yahoo · Aug 6, 2026
CG Oncology, Inc. (CGON) Reports Q2 Loss, Misses Revenue Estimates
CG Oncology, Inc. (CGON) delivered earnings and revenue surprises of -28.57% and -59.02%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
